Pay in 4 interest-free payments of $6.04 Learn more
Ships within 48 hours · Estimated delivery Aug 23 - Aug 28
Reports and Surveys | January 22, 2026 We conducted a cost-benefit analysis of glucagon-like peptide-1 agonists (GLP-1s) using data from SHAPE, our proprietary health data warehouse
You've got this
Sodiumglucose cotransporter-2 inhibitors (SGLT2i) For the only 1A recommendation in the entire document: KDIGO recommends treating patients with T2D, CKD, and an eGFR 30 ml/min per 1.73 m2 with an SGLT2i (1A)
There are key differences between the two, and one is significantly more harmful than the other
doi: 10.2337/dc19-0749 23 ZinmanBBhosekarVBuschRHolstILudvikBThielkeDet al
US$ 20.86
US$ 25.79
US$ 25.40
US$ 28.43
US$ 25.56
US$ 27.17
US$ 24.50
US$ 27.42
US$ 22.39
